<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Discontinuing antidepressant medications in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Discontinuing antidepressant medications in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Discontinuing antidepressant medications in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Hirsch, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert J Birnbaum, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter P Roy-Byrne, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David Solomon, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 21, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H207921">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who stop their antidepressants are at risk for the antidepressant discontinuation syndrome, especially if they abruptly stop the drug, taper it too quickly, or switch to a new antidepressant with a different pharmacodynamic profile [
         <a href="#rid1">
          1-5
         </a>
         ]. Although discontinuation symptoms are generally mild and self-limiting, in some cases they are severe [
         <a href="#rid6">
          6
         </a>
         ], which has given rise to online forums such as
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.survivingantidepressants.org%2Fguidelines%2F&amp;token=wCm60C9lKAKrNGD9Gwrm4eV1MWk%2FCNDpGNqle0i8WCFh2ODLX%2FVKWWbFt2EHtB82qz22%2BmAAnlGmMRElDGx9qA%3D%3D&amp;TOPIC_ID=105323" target="_blank">
          Surviving Antidepressants
         </a>
         .
        </p>
        <p>
         This topic discusses the antidepressant discontinuation syndrome and discontinuing antidepressants without switching to another drug. Choosing an alternative treatment for patients with depression, as well as switching antidepressant drugs, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14685.html" rel="external">
          "Unipolar depression in adults: Choosing treatment for resistant depression"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1716.html" rel="external">
          "Switching antidepressant medications in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1270506038">
         <span class="h1">
          INDICATIONS FOR DISCONTINUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Following a clinical assessment and discussion with the patient, discontinuing antidepressant medications may be indicated for the following reasons:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lack of efficacy – Patients with acute psychiatric disorders who do not respond satisfactorily to an antidepressant drug may switch to another antidepressant medication, psychotherapy, or neuromodulation. This topic discusses discontinuing antidepressants without switching to another drug. Choosing an alternative treatment for patients with depression, as well as switching antidepressant drugs, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14685.html" rel="external">
          "Unipolar depression in adults: Choosing treatment for resistant depression"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1716.html" rel="external">
          "Switching antidepressant medications in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serious adverse effect.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unintended pregnancy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Imminent surgery or medical emergency.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sequential treatment – Patients with unipolar major depression who successfully complete acute phase pharmacotherapy may switch to psychotherapy for maintenance treatment; this strategy is called sequential treatment. (See
         <a class="medical medical_review" href="/z/d/html/14674.html" rel="external">
          "Unipolar depression in adults: Continuation and maintenance treatment", section on 'Sequential treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Successful acute and maintenance treatment – Acute and maintenance phase treatment may be successful such that patients recover for a substantial length of time (eg, two years). At that point, it is reasonable for patients who are not at an elevated risk of recurrence to discontinue pharmacotherapy. Risk factors for recurrence of unipolar major depression are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14674.html" rel="external">
          "Unipolar depression in adults: Continuation and maintenance treatment", section on 'Indications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3122943290">
         <span class="h1">
          ADVERSE CONSEQUENCES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Stopping antidepressants may lead to the antidepressant discontinuation syndrome. Among patients who are successfully treated with antidepressants, another risk of stopping the medication is recurrence of the underlying disorder.
        </p>
        <p class="headingAnchor" id="H209967">
         <span class="h2">
          Discontinuation syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         The antidepressant discontinuation syndrome is characterized by sudden onset of symptoms shortly after stopping the antidepressant or tapering it too quickly; the syndrome is typically self-limited when untreated, and resolves after restarting the antidepressant [
         <a href="#rid4">
          4
         </a>
         ]. The morbidity and management of the antidepressant discontinuation is described in the subsections below.
        </p>
        <p>
         Recognition of the antidepressant discontinuation syndrome extends as far back as 1959 [
         <a href="#rid7">
          7
         </a>
         ]. As an example, an observational study of 85 patients who were treated with
         <a class="drug drug_general" data-topicid="8554" href="/z/d/drug information/8554.html" rel="external">
          imipramine
         </a>
         for depressive syndromes found that discontinuation symptoms occurred in 18 percent [
         <a href="#rid8">
          8
         </a>
         ]. The symptoms included restlessness and nausea, were generally mild, and lasted approximately three days in the absence of treatment.
        </p>
        <p class="headingAnchor" id="H707843304">
         <span class="h3">
          Overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no standard definition for the antidepressant discontinuation syndrome. Nevertheless, it is generally thought that the syndrome comprises one or more adverse effects, such as dizziness, fatigue, headache, and nausea, which can occur when antidepressants that have been taken continuously for at least several (eg, four) weeks are discontinued [
         <a href="#rid1">
          1-5,9-14
         </a>
         ]. The syndrome is especially likely to occur if patients:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abruptly stop antidepressants
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Taper antidepressants too quickly (eg, for two to seven days)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Switch to a new antidepressant with a different pharmacodynamic profile
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Skip a few (eg, three or four) consecutive doses of antidepressants with relatively short half-lives or nonlinear pharmacokinetics, such as
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
         or
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
        </p>
        <p>
        </p>
        <p>
         In addition, it is conceivable that discontinuation symptoms may arise if the patient switches from a branded formulation to a generic, due to differences in bioequivalence [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         All antidepressant classes can cause the antidepressant discontinuation syndrome, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors, atypical antidepressants, serotonin modulators, tricyclics, and monoamine oxidase inhibitors [
         <a href="#rid3">
          3-5,9-11,16,17
         </a>
         ]. Although discontinuation symptoms have been best characterized in patients with unipolar depression who abruptly stop SSRIs, they can occur in patients taking antidepressants regardless of diagnosis [
         <a href="#rid5">
          5,9-11,14
         </a>
         ].
        </p>
        <p>
         It appears that many patients abruptly discontinue their antidepressant. In a retrospective study of 66 patients who were treated with SSRIs for at least two months, more than 20 percent abruptly stopped their medication; this was usually on their initiative rather than the advice of their clinician [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         The pathophysiology of the antidepressant discontinuation syndrome is not clear. For SSRIs, the association between shorter elimination half-life and increased frequency and severity of discontinuation symptoms suggests that reduced availability of serotonin in the brain is involved in the syndrome [
         <a href="#rid14">
          14,19
         </a>
         ]. During SSRI treatment, the density and sensitivity of serotonin receptors are downregulated, which may leave patients vulnerable to a deficiency of serotonin when SSRIs are stopped [
         <a href="#rid9">
          9
         </a>
         ]. Other neurotransmitters such as acetylcholine, dopamine, glutamate, and norepinephrine may also be involved in the discontinuation syndrome, given the wide range of symptoms that can occur as part of the syndrome (see
         <a class="local">
          'Clinical features'
         </a>
         below), and that serotonergic neurons affect other neurotransmitter systems [
         <a href="#rid9">
          9,14,19
         </a>
         ]. In addition, polymorphisms in hepatic enzyme genes that affect the rate of antidepressant metabolism, and polymorphisms in neurotransmitter receptor genes, may possibly be related to discontinuation symptoms [
         <a href="#rid3">
          3,20
         </a>
         ]. Psychologic factors, including negative expectations that amplify discontinuation symptoms (nocebo effects), may also have a role [
         <a href="#rid9">
          9,21,22
         </a>
         ].
        </p>
        <p>
         Clinicians can assess discontinuation symptoms by asking open-ended questions such as, “How have you felt since stopping the drug, have you had any new problems?” [
         <a href="#rid10">
          10
         </a>
         ]. The value of this assessment is increased by establishing the patient’s clinical status prior to discontinuing the drug. For patients who report new onset symptoms, clinicians should rule out other causes, such as psychiatric disorders, general medical conditions, or concurrent drugs [
         <a href="#rid3">
          3,14
         </a>
         ].
        </p>
        <p>
         In many studies of the discontinuation syndrome, investigators used the Discontinuation-Emergent Signs and Symptoms checklist, which includes 43 items and is administered by the clinician or self-report [
         <a href="#rid10">
          10,23
         </a>
         ]. Some studies have defined the discontinuation syndrome as the presence of a minimum number of signs and symptoms (eg, at least two or four) [
         <a href="#rid6">
          6
         </a>
         ]; however, there is no standardized cutoff and using this instrument is not part of routine clinical practice.
        </p>
        <p>
         The American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) describes the clinical features of the antidepressant discontinuation syndrome in the section entitled “Medication-Induced Movement Disorders and Other Adverse Effects of Medication” [
         <a href="#rid3">
          3
         </a>
         ]. However, DSM-5 does not provide specific criteria for diagnosing the syndrome. Some studies use the term “withdrawal reaction” or “withdrawal syndrome” instead of discontinuation syndrome [
         <a href="#rid6">
          6,13
         </a>
         ].
        </p>
        <p>
         Evidence regarding the antidepressant discontinuation syndrome is limited in part because many of the studies consist of case reports rather than prospective studies [
         <a href="#rid14">
          14
         </a>
         ]. In addition, many randomized trials of antidepressants were not designed to assess discontinuation symptoms, and the trials often lasted only six weeks, which may not be long enough to generate discontinuation effects in some patients.
        </p>
        <p class="headingAnchor" id="H387309194">
         <span class="h3">
          Incidence and risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the reported incidence of the antidepressant discontinuation syndrome varies widely [
         <a href="#rid3">
          3,6,9,14
         </a>
         ], many studies suggest the syndrome occurs in approximately 30 percent of patients who stop an antidepressant. As an example, a meta-analysis of nine randomized trials of SSRIs and
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         (sample size not reported) indicates that discontinuation symptoms occur in 31 percent of patients; however, heterogeneity across studies is large [
         <a href="#rid24">
          24
         </a>
         ]. In addition, a review in the National Institute for Health and Care Excellence practice guideline for depression found that symptoms occur in approximately 30 percent of patients [
         <a href="#rid5">
          5
         </a>
         ]. A prior meta-analysis, which included 14 randomized trials and observational studies (n &gt;4000 patients), found that the incidence was 56 percent [
         <a href="#rid6">
          6
         </a>
         ]. However, this estimate appears to be excessive, given that more than 75 percent of the patients were assessed with online surveys, in which the incidence of discontinuation effects was self-defined and probably affected by attributional bias [
         <a href="#rid24">
          24,25
         </a>
         ].
        </p>
        <p>
         Although some studies suggest the frequency of specific symptoms varies across different antidepressant classes [
         <a href="#rid4">
          4
         </a>
         ], this is not established.
        </p>
        <p>
         Risk factors for the antidepressant discontinuation syndrome include [
         <a href="#rid1">
          1-5,9,14,15,26-29
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abrupt discontinuation or tapering the medication too quickly (eg, over two to seven days)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Shorter antidepressant elimination half-life (eg, &lt;24 hours)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonlinear antidepressant pharmacokinetics
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lack of an active metabolite
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lower receptor binding affinity of the antidepressant
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anxiety symptoms at the onset of antidepressant treatment
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Higher antidepressant doses and serum concentrations prior to discontinuation
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Longer duration of treatment at therapeutic doses (eg, at least four to eight weeks)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prior history of discontinuation symptoms
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Concurrent centrally acting medications (eg, antihypertensives, antihistamines, or antipsychotics)
        </p>
        <p>
        </p>
        <p>
         Sociodemographic factors such as age and sex do not appear to be risk factors for discontinuation symptoms.
        </p>
        <p class="headingAnchor" id="H782685431">
         <span class="h3">
          Clinical features
         </span>
         <span class="headingEndMark">
          —
         </span>
         The antidepressant discontinuation syndrome is characterized by a wide range of new onset somatic and neuropsychiatric symptoms that can occur in any combination; some reviews have identified approximately 50 to 80 symptoms across 10 organ systems [
         <a href="#rid3">
          3-5,9,11,12,14
         </a>
         ]. None of the symptoms are pathognomonic.
        </p>
        <p>
         Based upon results from multiple studies, the most common discontinuation symptoms appear to be [
         <a href="#rid1">
          1-4,6,9-12,14,15,26,30
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dizziness
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fatigue
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Headache
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nausea
        </p>
        <p>
        </p>
        <p>
         Other common discontinuation symptoms include [
         <a href="#rid1">
          1-4,6,9-12,14,15,26,30
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Agitation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anxiety
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chills without fever
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diaphoresis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dysphoria
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Electric shock-like sensations (“brain zaps”)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Insomnia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Irritability
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Myalgias
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Paresthesias
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rhinorrhea
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tremor
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vivid dreams
        </p>
        <p>
        </p>
        <p>
         Less common or rare symptoms, such as those described in case reports, include loss of balance [
         <a href="#rid4">
          4,9,10,15
         </a>
         ], cognitive impairment [
         <a href="#rid4">
          4,9,10,30
         </a>
         ], loose stools/diarrhea [
         <a href="#rid4">
          4,6,9,10,14
         </a>
         ], extrapyramidal symptoms [
         <a href="#rid4">
          4
         </a>
         ], hypertension [
         <a href="#rid31">
          31
         </a>
         ], hypomania and mania [
         <a href="#rid32">
          32,33
         </a>
         ], psychosis (eg, auditory and visual hallucinations) [
         <a href="#rid34">
          34-36
         </a>
         ], sexual dysfunction [
         <a href="#rid37">
          37
         </a>
         ], suicidal ideation [
         <a href="#rid6">
          6
         </a>
         ], tinnitus [
         <a href="#rid3">
          3,11
         </a>
         ], and vomiting [
         <a href="#rid2">
          2,4,9,10,12
         </a>
         ].
        </p>
        <p>
         Onset of the antidepressant discontinuation syndrome typically occurs within a few (eg, one to four) days of abruptly stopping antidepressants or tapering them too quickly [
         <a href="#rid1">
          1-5,11,14,15,27,34,38,39
         </a>
         ]. However, symptoms may not emerge until one or more weeks has elapsed since the last dose, especially for drugs with relatively long elimination half-lives, such as
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         .
        </p>
        <p>
         The antidepressant discontinuation syndrome is usually mild and dissipates spontaneously over one to three weeks; however, distressing symptoms can persist for a month or longer, and some studies report protracted cases lasting for one year and beyond [
         <a href="#rid3">
          3-6,9,11,12,14,30
         </a>
         ]. Symptoms can interfere with functioning, and may rarely lead to hospitalization, particularly if discontinuation occurs abruptly. Some patients may be reluctant to discontinue their antidepressant because symptoms are aversive, whereas other patients may become alarmed and refuse subsequent treatment with antidepressants.
        </p>
        <p>
         Although the adverse effects of stopping antidepressants (eg, dysphoria, insomnia, and nausea) can overlap with symptoms that arise from stopping addictive substances such as alcohol, opioids, or stimulants, the antidepressant discontinuation syndrome differs from substance-related and addiction disorders [
         <a href="#rid1">
          1-5,19,34
         </a>
         ]. Antidepressants are not addictive in that they do not cause reinforcing or euphoric effects, and patients do not neglect important occupational or social activities due to using antidepressants; rather, antidepressants typically improve functioning. In addition, patients do not crave antidepressants, spend a large amount of time obtaining or using antidepressants, or escalate the dose unless directed to do so by the prescribing clinician. Nor do antidepressants have street market value among individuals with substance-related and addictive disorders. Rather, the antidepressant discontinuation syndrome is a normal physiologic response that can occur after patients are treated with an antidepressant for a sufficient length of time (eg, four weeks) and then stop the medication [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Some symptoms of the antidepressant discontinuation syndrome, including dysphoria, fatigue, and insomnia, can also occur in patients with recurrences of anxiety and depressive disorders [
         <a href="#rid3">
          3-5,9,11,14,15
         </a>
         ]. However, other symptoms of the discontinuation syndrome, such as dizziness, electric-like shock sensations, nausea, and paresthesias, are not characteristic of anxiety and depressive disorders. Furthermore, resuming the discontinued antidepressant generally resolves the discontinuation syndrome within days (eg, one to three), whereas relapses of anxiety and depressive disorders often require weeks or months to remit after reintroducing the antidepressant or may require a different treatment.
        </p>
        <p>
         In addition, discontinuation symptoms may be mistaken for other general medical conditions [
         <a href="#rid5">
          5,14,15
         </a>
         ]. One case report described discontinuation symptoms from
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
         that were initially mistaken for stroke [
         <a href="#rid40">
          40
         </a>
         ] and another case report described evaluation and treatment by a neurologist and otolaryngologist for symptoms induced by stopping
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2562357161">
         <span class="h3">
          Prevention and management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Strategies for preventing the antidepressant discontinuation syndrome include educating patients to not abruptly stop their medication and to not taper medications too quickly. (See
         <a class="local">
          'General approach to discontinuing antidepressants'
         </a>
         below.)
        </p>
        <p>
         For patients who develop the antidepressant discontinuation syndrome after abruptly stopping treatment, we resume the medication at the dose that was used prior to discontinuation [
         <a href="#rid3">
          3,4,9,14
         </a>
         ]. However, if restarting the same antidepressant is contraindicated (eg, it was abruptly stopped due to rash or patient declines), we suggest using another antidepressant with a similar pharmacodynamic profile. As an example,
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         can be substituted for
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         . When the discontinuation symptoms abate, we discontinue the antidepressant using the general approach. (See
         <a class="local">
          'General approach to discontinuing antidepressants'
         </a>
         below.)
        </p>
        <p>
         If the discontinuation syndrome occurs in the context of tapering the antidepressant according to the general approach, management depends upon the severity of symptoms and time of onset [
         <a href="#rid4">
          4,5,9,15,29,38,39,42-45
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mild discontinuation symptoms that occur during a two- to four-week taper are usually managed with reassurance and watchful waiting.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If moderate to severe discontinuation symptoms occur during a two- to four-week taper, clinicians can extend the duration of the taper (eg, discontinue the antidepressant over 6 to 12 weeks). In addition, the antidepressant dose can be tapered by a fixed percent (eg, approximately 25 percent) rather than fixed amount. Thus, the absolute amount of each dose decrease is progressively smaller, until the last several doses, at which point the same small decrements are prescribed. As an example,
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         150 mg/day can be tapered using a liquid formulation as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Week 1 – 110 mg/day
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Week 2 – 80 mg/day
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Week 3 – 60 mg/day
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Week 4 – 45 mg/day
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Week 5 – 35 mg/day
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Week 6 – 25 mg/day
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Week 7 – 15 mg/day
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Week 8 – 10 mg/day
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Week 9 – 5 mg/day
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Week 10 – 5 mg/day
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Week 11 – Stop
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Liquid formulations are available for slowly tapering other SSRIs, including
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         ,
         <a class="drug drug_general" data-topicid="9046" href="/z/d/drug information/9046.html" rel="external">
          escitalopram
         </a>
         ,
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Alternatively, if moderate to severe discontinuation symptoms occur during a two- to four-week taper, patients may choose to abruptly stop the drug. Some patients may prefer more severe symptoms for a relatively short time, rather than less intense symptoms for a longer time.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If moderate to severe symptoms arise after the drug is tapered and stopped, the antidepressant is restarted at the dose at which there were no symptoms; the discontinuation syndrome should resolve within a few days (eg, one to three). The taper is then recommenced at a slower pace (eg, 6 to 12 weeks) than the initial taper, and the antidepressant dose can be decreased by a fixed percent (eg, 25 percent) with each reduction until the last several doses, at which point small decrements are prescribed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who have difficulty tapering off of an SSRI (eg,
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
         ) or
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         , a reasonable alternative is to immediately switch to
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         10 to 20 mg per day; fluoxetine can then be tapered over one to two weeks. (See
         <a class="local">
          'SSRIs'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If patients refuse to restart an antidepressant, it is reasonable to prescribe a short course (eg, one to two weeks) of a benzodiazepine such as
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         or
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         [
         <a href="#rid44">
          44,46
         </a>
         ]. Clonazepam is started at 0.25 to 0.5 mg once or twice daily and titrated up to 1 mg two or three times daily, based upon response and side effects. Following resolution of discontinuation symptoms, clonazepam is tapered by 20 to 25 percent every week.
        </p>
        <p>
        </p>
        <p>
         Rarely, patients with episodes of the antidepressant discontinuation syndrome require hospitalization, especially if it includes severe symptoms such as mania and/or psychosis [
         <a href="#rid4">
          4
         </a>
         ]. For manic or psychotic symptoms, we suggest using standard treatments, such as a second-generation antipsychotic (eg,
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         or
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/679.html" rel="external">
          "Bipolar mania and hypomania in adults: Choosing pharmacotherapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/17193.html" rel="external">
          "Psychosis in adults: Epidemiology, clinical manifestations, and diagnostic evaluation", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4017091627">
         <span class="h2">
          Recurrence of underlying disorder
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients who are successfully treated by antidepressants, recurrence of the disorder that prompted treatment can occur if the drug is discontinued, and may be more likely if discontinuation occurs abruptly [
         <a href="#rid3">
          3,23,26,27,47-50
         </a>
         ]. In one study, patients with acute unipolar major depression were initially treated with open-label
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         20 mg/day for 12 weeks; those who responded (n = 395) were randomly assigned to abruptly stop the drug and substitute placebo, or to continue fluoxetine [
         <a href="#rid27">
          27
         </a>
         ]. Recurrence of depression occurred in more than twice as many patients who abruptly stopped fluoxetine, compared with patients who did not (39 versus 17 percent).
        </p>
        <p>
         Additional information about recurrence in the absence of maintenance treatment is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14674.html" rel="external">
          "Unipolar depression in adults: Continuation and maintenance treatment", section on 'Relapse/recurrence in the absence of treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H211109">
         <span class="h1">
          GENERAL APPROACH TO DISCONTINUING ANTIDEPRESSANTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Education about the potential for and nature of the antidepressant discontinuation syndrome at the onset of treatment may prevent patients from skipping doses or abruptly stopping antidepressants on their own and help reduce anxiety should adverse discontinuation effects occur [
         <a href="#rid4">
          4,14,15,38,39,42
         </a>
         ]. Patients may be reassured to learn that discontinuation symptoms are not unique to antidepressants and do not indicate that antidepressants cause addiction or dependence.
        </p>
        <p>
         For patients who are treated with an antidepressant for at least several (eg, four to eight) weeks, and are stopping the drug without switching to another antidepressant, the general approach for minimizing discontinuation symptoms is to progressively taper the dose by a fixed amount or percent for at least two to four weeks [
         <a href="#rid4">
          4,14,42,51
         </a>
         ]. For patients who are treated with antidepressants for a briefer time period (eg, two to three weeks), the drug can be tapered over one to two weeks, and for patients treated for less than two weeks, the drug can be abruptly stopped. This general approach is consistent with multiple treatment guidelines [
         <a href="#rid5">
          5,38,39,52,53
         </a>
         ].
        </p>
        <p>
         The specific duration of the taper depends primarily upon the clinical urgency and the drug’s elimination half-life. Abrupt discontinuation may be necessary in some situations (eg, severe adverse effect, unintended pregnancy, or urgent surgery). Drugs with a longer half-life (eg, ≥24 hours) can generally be tapered over two to three weeks, whereas drugs with shorter half-lives (eg, &lt;24 hours) are tapered over four weeks if it is practical. Although some studies report tapering schedules lasting for nine months or longer [
         <a href="#rid9">
          9
         </a>
         ], this is not standard practice.
        </p>
        <p>
         For patients who suffer discontinuation symptoms despite a gradual taper, the duration of the taper is extended beyond four weeks; the pace depends upon what the patient can tolerate. (See
         <a class="local">
          'Prevention and management'
         </a>
         above.)
        </p>
        <p>
         Evidence supporting the general approach to discontinuing antidepressant drugs is limited:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A small, randomized trial compared tapering over three days with tapering over 14 days in patients who were treated with
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         ,
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
         , or
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         (n = 28), and found that the incidence of discontinuation and depressive symptoms was comparable (approximately 46 percent in each group) [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective study of patients treated with SSRIs for at least two months found that the mean number of discontinuation symptoms was greater in 14 patients who abruptly stopped their antidepressant, compared with 52 patients who tapered the drug over 2 to 16 weeks (12 versus 6 symptoms) [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective observational study of euthymic patients who discontinued their antidepressants (n = 224) found that the median time to recurrence of depression was shorter in patients who discontinued their antidepressant over one to seven days, compared with patients who discontinued their antidepressant over 14 or more days (three versus eight months) [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Discontinuing an antidepressant may necessitate dose adjustments of co-prescribed medications because some antidepressants affect the metabolism of other drugs. As an example,
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         potently inhibits the hepatic cytochrome enzyme CYP2D6. Specific interactions of antidepressants with other medications may be determined using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included in UpToDate.
        </p>
        <p class="headingAnchor" id="H211589">
         <span class="h1">
          SPECIFIC DRUGS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Each subsection below describes aspects of the antidepressant discontinuation syndrome that are specific to individual antidepressants within each antidepressant class. In addition, aspects of the standard approach that vary for individual antidepressants are discussed below. The individual antidepressants that constitute each drug class are listed in the table  (
         <a class="graphic graphic_table graphicRef53818" href="/z/d/graphic/53818.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H211595">
         <span class="h2">
          SSRIs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Discontinuation symptoms can occur with any selective serotonin reuptake inhibitor (SSRI), and for each SSRI, the incidence and severity varies widely across different studies [
         <a href="#rid9">
          9,14
         </a>
         ]. One review estimated that the incidence of clinically significant discontinuation symptoms with SSRIs was approximately 40 percent [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         Randomized trials and observational studies indicate that the risk of discontinuation symptoms differs according to the drug’s elimination half-life [
         <a href="#rid2">
          2-5,9-12,14,23,26,27,47-50,54-56
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Least risk –
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          Fluoxetine
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intermediate risk –
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          Citalopram
         </a>
         ,
         <a class="drug drug_general" data-topicid="9046" href="/z/d/drug information/9046.html" rel="external">
          escitalopram
         </a>
         , and
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Greatest risk –
         <a class="drug drug_general" data-topicid="8474" href="/z/d/drug information/8474.html" rel="external">
          Fluvoxamine
         </a>
         and
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
        </p>
        <p>
        </p>
        <p>
         As an example, across different randomized trials in which an SSRI was abruptly stopped after 12 weeks of treatment, the incidence of discontinuation symptoms in patients treated with
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         or
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
         was 7 and 35 percent [
         <a href="#rid11">
          11
         </a>
         ]. In addition, an observational study of clinician initiated reports of adverse events found that discontinuation symptoms occurred 10 times more often with paroxetine than
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         and 100 times more often with paroxetine than fluoxetine [
         <a href="#rid34">
          34
         </a>
         ]. Other observational studies suggest that the risk of discontinuation symptoms with
         <a class="drug drug_general" data-topicid="8474" href="/z/d/drug information/8474.html" rel="external">
          fluvoxamine
         </a>
         is high and comparable to that of paroxetine [
         <a href="#rid10">
          10,57,58
         </a>
         ]. As an example, a retrospective study found that among patients treated with fluvoxamine (n = 43) or paroxetine (n = 50), the frequency of discontinuation symptoms was comparable (14 and 20 percent of patients) [
         <a href="#rid59">
          59
         </a>
         ]. Other factors that affect the frequency and severity of discontinuation symptoms are discussed elsewhere in this topic. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
         To prevent onset of the antidepressant discontinuation syndrome with SSRIs, tapering over two to four weeks prior to discontinuation works well for the large majority of patients. (See
         <a class="local">
          'General approach to discontinuing antidepressants'
         </a>
         above.)
        </p>
        <p>
         However,
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         can be tapered over one to two weeks due to the relatively long elimination half-life of the drug (four to six days) and its active metabolite norfluoxetine (4 to 16 days). Alternatively, it is reasonable to abruptly stop fluoxetine [
         <a href="#rid2">
          2,14,29
         </a>
         ]. Support for abrupt discontinuation includes randomized trials that found discontinuation symptoms were comparable for fluoxetine and placebo when placebo was abruptly substituted for fluoxetine [
         <a href="#rid23">
          23,47
         </a>
         ]. In one trial, acutely depressed patients (n = 395) who responded to 12 weeks of fluoxetine 20 mg/day were randomly assigned to either continue fluoxetine or to abruptly switch to placebo [
         <a href="#rid27">
          27
         </a>
         ]. During six weeks of follow-up, the incidence of adverse events in the two groups was similar. A subsequent, randomized trial in patients treated with fluoxetine (n = 37; mean dose 29 mg/day), for an average duration of one year, found that placebo substitution did not cause any discontinuation symptoms [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          Paroxetine
         </a>
         is discontinued over three to four weeks because it is most likely to cause discontinuation symptoms [
         <a href="#rid1">
          1
         </a>
         ]. As an example, paroxetine 50 mg per day is tapered to 40 mg per day for week 1, 30 mg per day for week 2, 20 mg per day for week 3, and 10 mg per day for week 4. The drug is then stopped, unless discontinuation symptoms persist, in which case 5 mg/day can be prescribed for at least one or two additional weeks.
        </p>
        <p>
         Patients who have difficulty tapering off of
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
         or other SSRIs may benefit from immediately switching to
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         10 to 20 mg per day [
         <a href="#rid38">
          38,39,42,43
         </a>
         ]. Patients switched to fluoxetine 20 mg per day continue the dose for one to two weeks after the discontinuation symptoms have abated, decrease the dose to 10 mg per day for one to two weeks, and then stop the drug. Patients switched to fluoxetine 10 mg per day continue the dose for one to two weeks after the discontinuation symptoms have resolved, after which fluoxetine is stopped. For patients who have difficulty discontinuing fluoxetine 10 mg per day, a liquid formulation is available for administering 5 mg per day for one to two weeks before stopping the drug.
        </p>
        <p>
         The pharmacology, administration, and side effects of SSRIs are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14675.html" rel="external">
          "Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H211781">
         <span class="h2">
          SNRIs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Abrupt discontinuation of serotonin-norepinephrine reuptake inhibitors (SNRIs), or tapering them too quickly, often causes the antidepressant discontinuation syndrome (see
         <a class="local">
          'Discontinuation syndrome'
         </a>
         above) [
         <a href="#rid17">
          17
         </a>
         ]. To prevent discontinuation symptoms, SNRIs are usually tapered gradually prior to discontinuation. (See
         <a class="local">
          'General approach to discontinuing antidepressants'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Desvenlafaxine
         </strong>
         – Abrupt discontinuation of
         <a class="drug drug_general" data-topicid="8944" href="/z/d/drug information/8944.html" rel="external">
          desvenlafaxine
         </a>
         50 mg/day or 100 mg/day may cause the discontinuation syndrome [
         <a href="#rid60">
          60,61
         </a>
         ]. For patients treated with higher doses who decide to stop the medication and are not switching to another antidepressant, we suggest tapering the drug over two to four weeks to reduce the risk of discontinuation symptoms (such as dizziness, headache, insomnia, irritability, and nausea) [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Duloxetine
         </strong>
         – Based upon multiple randomized trials, we suggest tapering
         <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">
          duloxetine
         </a>
         over two to four weeks to reduce discontinuation symptoms. A pooled analysis of six randomized trials, lasting eight or nine weeks, compared duloxetine (40 to 120 mg/day) with placebo in patients with acute unipolar major depression (n = 870) [
         <a href="#rid51">
          51
         </a>
         ]. Following abrupt discontinuation of treatment, the incidence of one or more discontinuation symptoms was greater with duloxetine than placebo (44 versus 23 percent). Symptoms that occurred more often with duloxetine included dizziness, nausea, and headache.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, a subsequent trial suggests that tapering
         <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">
          duloxetine
         </a>
         for one to two weeks may be a reasonable alternative [
         <a href="#rid29">
          29
         </a>
         ]. A 10-week randomized trial compared duloxetine (mean dose 108 mg/day) with placebo for 10 weeks in patients with acute generalized anxiety disorder [
         <a href="#rid62">
          62
         </a>
         ]. Afterwards, pharmacotherapy was tapered and stopped over one to two weeks, depending upon the dose. Among the 194 patients who entered the drug-tapering phase, the incidence of one or more discontinuation symptoms was comparable with duloxetine and placebo (19 and 15 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Levomilnacipran
         </strong>
         – We suggest that doses greater than 20 mg per day be tapered and discontinued over two to four weeks, consistent with procedures in the registration trials [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Milnacipran
         </strong>
         – We suggest tapering
         <a class="drug drug_general" data-topicid="9506" href="/z/d/drug information/9506.html" rel="external">
          milnacipran
         </a>
         over two to four weeks prior to discontinuation [
         <a href="#rid64">
          64
         </a>
         ]. In a randomized trial that included 46 patients with acute unipolar major depression who were treated with milnacipran 50 mg twice daily for six weeks, abrupt discontinuation caused at least one discontinuation symptom (eg, anxiety) in 13 percent; among patients who were treated for 24 weeks (n = 20), at least one discontinuation symptom occurred in 30 percent [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Venlafaxine
         </strong>
         – We suggest tapering the daily dose of
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         by 37.5 to 75 mg each week over four weeks to reduce discontinuation symptoms [
         <a href="#rid15">
          15,29
         </a>
         ]. This schedule applies to both the immediate- and extended-release formulations. As an example, patients starting at 300 mg can be tapered by increments of 75 mg each week, whereas patients starting at 150 mg can be tapered by 37.5 mg each week. Patients starting at 225 mg can initially be tapered by 75 mg each week and then switch to 37.5 mg each week. Patients who have difficulty tapering off of venlafaxine may benefit from switching to
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         10 to 20 mg per day; the fluoxetine can then be tapered off, typically without discontinuation effects [
         <a href="#rid38">
          38,39,42,43
         </a>
         ]. (See
         <a class="local">
          'SSRIs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Abrupt discontinuation of
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         commonly causes discontinuation symptoms due to its relatively short elimination half-life and that of its active metabolite
         <a class="drug drug_general" data-topicid="8944" href="/z/d/drug information/8944.html" rel="external">
          desvenlafaxine
         </a>
         [
         <a href="#rid26">
          26,28,54,66-68
         </a>
         ]. Although venlafaxine extended-release has a longer elimination half-life than venlafaxine immediate release, the extended formulation half-life is nonetheless relatively short. The half-lives are approximately as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          Venlafaxine
         </a>
         immediate-release – 5 hours
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8944" href="/z/d/drug information/8944.html" rel="external">
          Desvenlafaxine
         </a>
         immediate-release – 11 hours
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          Venlafaxine
         </a>
         extended-release – 11 hours
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8944" href="/z/d/drug information/8944.html" rel="external">
          Desvenlafaxine
         </a>
         extended-release – 13 hours
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The antidepressant discontinuation syndrome seen with
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         is similar to that seen with SSRIs, but can be more severe. As an example, an eight-week randomized trial that compared venlafaxine extended-release (mean dose 95 mg/day) with
         <a class="drug drug_general" data-topicid="9046" href="/z/d/drug information/9046.html" rel="external">
          escitalopram
         </a>
         (mean dose 12 mg/day) in 288 patients with acute unipolar major depression found that after the drugs were abruptly stopped, the average number of discontinuation symptoms was greater with venlafaxine than escitalopram (five versus two) [
         <a href="#rid55">
          55
         </a>
         ]. In addition, the incidence of 11 symptoms was greater in the venlafaxine group, including agitation, cognitive impairment, diaphoresis, dizziness, fatigue, nausea, restlessness, tremor, and unsteady gait. By contrast, escitalopram did not lead to a greater incidence of any discontinuation symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Discontinuation symptoms may perhaps be more likely to occur with
         <a class="drug drug_general" data-topicid="8944" href="/z/d/drug information/8944.html" rel="external">
          desvenlafaxine
         </a>
         or
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         than other SNRIs [
         <a href="#rid5">
          5,38,39
         </a>
         ]. A 10-week randomized trial compared venlafaxine extended-release (mean dose 184 mg/day),
         <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">
          duloxetine
         </a>
         (108 mg/day), and placebo in patients with acute generalized anxiety disorder [
         <a href="#rid62">
          62
         </a>
         ]. Afterwards, pharmacotherapy was tapered and stopped over one to two weeks, depending upon the dose. Among the 298 patients who entered the drug-tapering phase, the incidence of one or more discontinuation symptoms was greater with venlafaxine than placebo (27 versus 15 percent). By contrast, the incidence was comparable with duloxetine and placebo (19 and 15 percent of patients) and with venlafaxine and duloxetine.
        </p>
        <p>
        </p>
        <p>
         The pharmacology, administration, and side effects of SNRIs are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1713.html" rel="external">
          "Serotonin-norepinephrine reuptake inhibitors: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H212459">
         <span class="h2">
          Atypical antidepressants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atypical antidepressants include drugs that are not related to each other or to other drug classes.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Agomelatine
         </strong>
         – Abrupt cessation of agomelatine 25 mg per day does not cause discontinuation symptoms [
         <a href="#rid69">
          69
         </a>
         ]. For patients taking agomelatine 50 mg per day, we suggest tapering the dose to 25 mg for one week before stopping the drug.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bupropion
         </strong>
         – Although discontinuation symptoms from
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         are uncommon, nevertheless, we taper the drug over two weeks before stopping it, consistent with prudent care (see
         <a class="local">
          'General approach to discontinuing antidepressants'
         </a>
         above). One case report described discontinuation symptoms, including anxiety, headache, insomnia, irritability, and myalgias [
         <a href="#rid70">
          70
         </a>
         ]. (See
         <a class="local">
          'Discontinuation syndrome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mirtazapine
         </strong>
         – We suggest tapering the dose over two to four weeks. One report described a case in which abrupt cessation of
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          mirtazapine
         </a>
         led to discontinuation symptoms, including anxiety, dizziness, insomnia, nausea, and paresthesias [
         <a href="#rid71">
          71
         </a>
         ]; another case report described severe anxiety in the form of new onset panic attacks when mirtazapine was abruptly withdrawn [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The pharmacology, administration, and side effects of atypical antidepressants are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/85816.html" rel="external">
          "Atypical antidepressants: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H212677">
         <span class="h2">
          Serotonin modulators
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nefazodone
         </strong>
         – We suggest tapering the dose over one to two weeks to reduce discontinuation symptoms. However, the evidence indicates that a reasonable alternative is to abruptly stop the drug. In one study, patients with acute unipolar major depression who responded to 16 weeks of
         <a class="drug drug_general" data-topicid="9684" href="/z/d/drug information/9684.html" rel="external">
          nefazodone
         </a>
         (n = 259) were randomly assigned to maintenance treatment with nefazodone or abrupt placebo substitution [
         <a href="#rid73">
          73
         </a>
         ]. Assessments 14 days after randomization found that the incidence of at least one new-onset or worsened adverse effect was comparable in patients who received active drug or placebo (17 and 21 percent of patients). At day 28, the incidence was again comparable with placebo and nefazodone (29 and 31). (See
         <a class="local">
          'Discontinuation syndrome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Trazodone
         </strong>
         –
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          Trazodone
         </a>
         is gradually tapered over two to four weeks prior to discontinuation. Rapid or abrupt discontinuation may be followed by discontinuation symptoms, including anxiety, headache, myalgia, nausea, and weakness [
         <a href="#rid74">
          74,75
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vilazodone
         </strong>
         – Discontinuation symptoms due to abrupt discontinuation of
         <a class="drug drug_general" data-topicid="16102" href="/z/d/drug information/16102.html" rel="external">
          vilazodone
         </a>
         have not been described. Nevertheless, for patients who take 20 to 40 mg per day, we suggest tapering the dose down to 10 mg per day over one to two weeks, prior to discontinuation [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vortioxetine
         </strong>
         – Clinicians can abruptly discontinue
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          vortioxetine
         </a>
         10 mg per day, consistent with procedures in the registration trials [
         <a href="#rid77">
          77
         </a>
         ]. For patients taking 15 or 20 mg per day, we suggest decreasing the dose to 10 mg per day for one week before stopping the drug, consistent with prescribing information in the vortioxetine label.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Evidence regarding minimal discontinuation symptoms with
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          vortioxetine
         </a>
         includes the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A review of registration trials by the US Food and Drug Administration found that abrupt discontinuation of
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          vortioxetine
         </a>
         10 mg per day did not cause discontinuation symptoms [
         <a href="#rid77">
          77
         </a>
         ]. However, abruptly discontinuing a dose of 15 or 20 mg per day caused dizziness, headache, mood lability, muscle tension, and/or rhinorrhea in approximately 5 percent of patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Three randomized trials lasting eight weeks compared the efficacy of
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          vortioxetine
         </a>
         (10, 15, or 20 mg/day) with placebo in patients with acute unipolar major depression (n &gt;1300), and then abruptly stopped the study drugs [
         <a href="#rid78">
          78
         </a>
         ]. During the subsequent two weeks, a pooled analysis found that the level of discontinuation symptoms was comparable for the two groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A maintenance treatment study compared
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          vortioxetine
         </a>
         (5 or 10 mg/day) with placebo for up to 64 weeks in patients who remitted from unipolar major depression (n = 396), and then abruptly stopped the study drugs [
         <a href="#rid79">
          79
         </a>
         ]. During the subsequent two weeks, the level of discontinuation symptoms was comparable for the two groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The safety of
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          vortioxetine
         </a>
         regarding the antidepressant discontinuation syndrome is probably due in part to its relatively long elimination half-life, which is 66 hours  (
         <a class="graphic graphic_table graphicRef88062" href="/z/d/graphic/88062.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The pharmacology, administration, and side effects of serotonin modulators are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/86265.html" rel="external">
          "Serotonin modulators: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H212829">
         <span class="h2">
          Tricyclics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tricyclic (and tetracyclic) antidepressants are generally tapered over two to four weeks [
         <a href="#rid29">
          29,80
         </a>
         ] (see
         <a class="local">
          'General approach to discontinuing antidepressants'
         </a>
         above). Abrupt discontinuation can cause discontinuation symptoms, including agitation, anxiety, chills, diaphoresis, headache, insomnia, irritability, malaise, myalgia, and nausea (see
         <a class="local">
          'Clinical features'
         </a>
         above), and may rarely cause akathisia, cardiac arrhythmia, and parkinsonism [
         <a href="#rid10">
          10,81,82
         </a>
         ].
        </p>
        <p>
         The pharmacology, administration, and side effects of tricyclics are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1717.html" rel="external">
          "Tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H212939">
         <span class="h2">
          MAOIs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Monoamine oxidase inhibitors (MAOIs) are generally tapered for at least four weeks prior to stopping the drug [
         <a href="#rid29">
          29
         </a>
         ]. Moderate to severe discontinuation symptoms that arise while tapering
         <a class="drug drug_general" data-topicid="9762" href="/z/d/drug information/9762.html" rel="external">
          phenelzine
         </a>
         or
         <a class="drug drug_general" data-topicid="10012" href="/z/d/drug information/10012.html" rel="external">
          tranylcypromine
         </a>
         are managed by resuming the daily dose at which there were no symptoms, and then tapering the dose more slowly (eg, phenelzine by 15 mg or tranylcypromine by 10 mg every two weeks [
         <a href="#rid29">
          29,81
         </a>
         ]). Abruptly stopping MAOIs can cause discontinuation symptoms, including anxiety, agitation, insomnia, chills, diaphoresis, headache, irritability, malaise, and nausea [
         <a href="#rid16">
          16,44,57,81
         </a>
         ] (see
         <a class="local">
          'Clinical features'
         </a>
         above). In addition, reports have described more serious discontinuation symptoms, including delirium, myoclonic jerks, and psychosis.
        </p>
        <p>
         The pharmacology, administration, and side effects of MAOIs are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1715.html" rel="external">
          "Monoamine oxidase inhibitors (MAOIs): Pharmacology, administration, safety, and side effects"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3518721457">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116503.html" rel="external">
          "Society guideline links: Depressive disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H213083">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/16338.html" rel="external">
          "Patient education: Coping with high drug prices (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/4868.html" rel="external">
          "Patient education: Depression in adults (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/4866.html" rel="external">
          "Patient education: Depression treatment options for adults (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/16279.html" rel="external">
          "Patient education: Coping with high prescription drug prices in the United States (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H213302">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications for discontinuation
         </strong>
         – Indications for discontinuing antidepressant medications include lack of efficacy, serious adverse effect, unintended pregnancy, and imminent surgery. (See
         <a class="local">
          'Indications for discontinuation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antidepressant discontinuation syndrome
         </strong>
         – The antidepressant discontinuation syndrome comprises one or more adverse effects that can occur if patients discontinue antidepressants that have been taken continuously for at least several (eg, four) weeks, especially if the medication is stopped abruptly or tapered too quickly. All antidepressant classes can cause the discontinuation syndrome. (See
         <a class="local">
          'Overview'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Incidence and risk factors
         </strong>
         – Multiple studies suggest the discontinuation syndrome occurs in approximately 30 percent of patients who stop an antidepressant. Risk factors include shorter antidepressant elimination half-life (eg, &lt;24 hours), higher antidepressant doses, and longer duration of treatment at therapeutic doses (eg, at least four to eight weeks). (See
         <a class="local">
          'Incidence and risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clinical features
         </strong>
         – The most common discontinuation symptoms appear to be:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Dizziness
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Fatigue
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Headache
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Nausea
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Other common symptoms include agitation, anxiety, chills, diaphoresis, dysphoria, electric shock-like sensations, insomnia, irritability, myalgias, paresthesias, rhinorrhea, tremor, and vivid dreams.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Onset of the antidepressant discontinuation syndrome typically occurs within a few days of abruptly stopping antidepressants or tapering them too quickly. The syndrome is usually mild and dissipates spontaneously over one to three weeks; however, symptoms can persist for a month or longer. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Prevention and management
         </strong>
         – Strategies for preventing the antidepressant discontinuation syndrome include educating patients to not abruptly stop their medication, and not tapering medications too quickly. For patients who develop the antidepressant discontinuation syndrome after abruptly stopping treatment, we generally resume the medication at the dose that was used prior to discontinuation. If the discontinuation syndrome occurs despite using a relatively gradual tapering schedule to stop the antidepressant, management of the syndrome depends upon the severity of symptoms and time of onset. (See
         <a class="local">
          'Prevention and management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General approach for discontinuing antidepressants
         </strong>
         – For most patients who are discontinuing an antidepressant after at least four to eight weeks of use, and are stopping the drug without switching to another antidepressant, we suggest tapering the dose over two to four weeks (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Exceptions include
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         , which can be stopped abruptly, and monoamine oxidase inhibitors (MAOIs), which are generally tapered for at least four weeks before stopping the drug.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients who are treated with an antidepressant for less time (eg, two to three weeks) can taper the drug over one to two weeks, and patients treated for less than two weeks can abruptly stop the drug. (See
         <a class="local">
          'General approach to discontinuing antidepressants'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Specific drugs
         </strong>
         – The general approach for discontinuing antidepressants may vary for individual antidepressants; the specific antidepressants that constitute each drug class below are listed in the table  (
         <a class="graphic graphic_table graphicRef53818" href="/z/d/graphic/53818.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Selective serotonin reuptake inhibitors (SSRIs)
         </strong>
         – Tapering SSRIs over two to four weeks prior to stopping the drug works well for a large majority of patients. However,
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         can be tapered over one to two weeks due to the relatively long elimination half-life of the drug and its active metabolite. Alternatively, it is reasonable to abruptly stop fluoxetine. (See
         <a class="local">
          'SSRIs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Serotonin-norepinephrine reuptake inhibitors
         </strong>
         <strong>
          (SNRIs)
         </strong>
         – SNRIs are usually tapered and discontinued over two to four weeks. Discontinuation symptoms may perhaps be more likely to occur with
         <a class="drug drug_general" data-topicid="8944" href="/z/d/drug information/8944.html" rel="external">
          desvenlafaxine
         </a>
         or
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         than other SNRIs. (See
         <a class="local">
          'SNRIs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Atypical antidepressants and serotonin modulators
         </strong>
         – Discontinuation symptoms and tapering schedules vary among atypical antidepressants and serotonin modulators. (See
         <a class="local">
          'Atypical antidepressants'
         </a>
         above and
         <a class="local">
          'Serotonin modulators'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Tricyclics
         </strong>
         – Tricyclic antidepressants are generally tapered over two to four weeks. (See
         <a class="local">
          'Tricyclics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          MAOIs
         </strong>
         – MAOIs are generally tapered for at least four weeks before stopping the drug. (See
         <a class="local">
          'MAOIs'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Howlett JR, Stein MB, Nemeroff CB. Paroxetine. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.385.
         </li>
         <li class="breakAll">
          Rosenbaum JF, Ionescu DF. Fluoxetine. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.335.
         </li>
         <li class="breakAll">
          American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, 2013.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haddad PM, Anderson IM. Recognising and managing antidepressant discontinuation symptoms. Advances in Psychiatric Treatment 2007; 13:447.
          </a>
         </li>
         <li class="breakAll">
          National Institute for Health and Care Excellence (NICE). Depression in adults: recognition and management. Clinical Guideline 90. Published October 2009, updated September 2020. https://www.nice.org.uk/guidance/cg90 (Accessed on December 31, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based? Addict Behav 2019; 97:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MANN AM, MACPHERSON AS. Clinical experience with imipramine (G22355) in the treatment of depression. Can Psychiatr Assoc J 1959; 4:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andersen H, Kristiansen ES. Tofranil-treatment of endogenous depressions. Acta Psychiatr Scand 1959; 34:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry 2019; 6:538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fava M. Prospective studies of adverse events related to antidepressant discontinuation. J Clin Psychiatry 2006; 67 Suppl 4:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fava GA, Gatti A, Belaise C, et al. Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review. Psychother Psychosom 2015; 84:72.
          </a>
         </li>
         <li class="breakAll">
          Roseboom, PH, Kalin, NH. Citalopram and escitalopram. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.431.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fava GA, Cosci F. Understanding and Managing Withdrawal Syndromes After Discontinuation of Antidepressant Drugs. J Clin Psychiatry 2019; 80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jha MK, Rush AJ, Trivedi MH. When Discontinuing SSRI Antidepressants Is a Challenge: Management Tips. Am J Psychiatry 2018; 175:1176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warner CH, Bobo W, Warner C, et al. Antidepressant discontinuation syndrome. Am Fam Physician 2006; 74:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gahr M, Schönfeldt-Lecuona C, Kölle MA, Freudenmann RW. Withdrawal and discontinuation phenomena associated with tranylcypromine: a systematic review. Pharmacopsychiatry 2013; 46:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fava GA, Benasi G, Lucente M, et al. Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review. Psychother Psychosom 2018; 87:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Geffen EC, Hugtenburg JG, Heerdink ER, et al. Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. Eur J Clin Pharmacol 2005; 61:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blier P, Tremblay P. Physiologic mechanisms underlying the antidepressant discontinuation syndrome. J Clin Psychiatry 2006; 67 Suppl 4:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murata Y, Kobayashi D, Imuta N, et al. Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome. J Clin Psychopharmacol 2010; 30:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kronenberg G, Desai D, Anghelescu I. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry 2019; 6:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bingel U, Placebo Competence Team. Avoiding nocebo effects to optimize treatment outcome. JAMA 2014; 312:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998; 44:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jauhar S, Hayes J. The war on antidepressants: What we can, and can't conclude, from the systematic review of antidepressant withdrawal effects by Davies and Read. Addict Behav 2019; 97:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Selvaraj S, Jauhar S, Baldwin DS, et al. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry 2019; 6:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tint A, Haddad PM, Anderson IM. The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study. J Psychopharmacol 2008; 22:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zajecka J, Fawcett J, Amsterdam J, et al. Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study. J Clin Psychopharmacol 1998; 18:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenbaum JF, Zajecka J. Clinical management of antidepressant discontinuation. J Clin Psychiatry 1997; 58 Suppl 7:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ogle NR, Akkerman SR. Guidance for the discontinuation or switching of antidepressant therapies in adults. J Pharm Pract 2013; 26:389.
          </a>
         </li>
         <li class="breakAll">
          Carpenter LL, Schatzberg AF. Sertraline. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.359.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Astorne Figari WJ, Herrmann S, Akogyeram C, Qian Q. New onset hypertension following abrupt discontinuation of citalopram. Clin Nephrol 2014; 82:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrade C. Antidepressant-withdrawal mania:a critical review and synthesis of the literature. J Clin Psychiatry 2004; 65:987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narayan V, Haddad PM. Antidepressant discontinuation manic states: a critical review of the literature and suggested diagnostic criteria. J Psychopharmacol 2011; 25:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Price JS, Waller PC, Wood SM, MacKay AV. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 1996; 42:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yasui-Furukori N, Kaneko S. Hallucination induced by paroxetine discontinuation in patients with major depressive disorders. Psychiatry Clin Neurosci 2011; 65:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benazzi F. Psychotic mania in bipolar II depression related to sertraline discontinuation. Can J Psychiatry 2002; 47:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Csoka AB, Shipko S. Persistent sexual side effects after SSRI discontinuation. Psychother Psychosom 2006; 75:187.
          </a>
         </li>
         <li class="breakAll">
          American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition. October, 2010. http://psychiatryonline.org/guidelines (Accessed on November 06, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition. Am J Psychiatry 2010; 167 (supplement):1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haddad PM, Devarajan S, Dursun SM. Antidepressant discontinuation (withdrawal) symptoms presenting as 'stroke'. J Psychopharmacol 2001; 15:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Einbinder E. Fluoxetine withdrawal? Am J Psychiatry 1995; 152:1235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schatzberg AF, Blier P, Delgado PL, et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry 2006; 67 Suppl 4:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benazzi F. SSRI discontinuation syndrome treated with fluoxetine. Int J Geriatr Psychiatry 1998; 13:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haddad PM. Antidepressant discontinuation syndromes. Drug Saf 2001; 24:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groot PC, van Os J. How user knowledge of psychotropic drug withdrawal resulted in the development of person-specific tapering medication. Ther Adv Psychopharmacol 2020; 10:2045125320932452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benazzi F. SSRI discontinuation syndrome related to fluvoxamine. J Psychiatry Neurosci 1998; 23:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Judge R, Parry MG, Quail D, Jacobson JG. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int Clin Psychopharmacol 2002; 17:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br J Psychiatry 2000; 176:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hindmarch I, Kimber S, Cockle SM. Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance. Int Clin Psychopharmacol 2000; 15:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Markowitz JS, DeVane CL, Liston HL, Montgomery SA. An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram. Int Clin Psychopharmacol 2000; 15:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perahia DG, Kajdasz DK, Desaiah D, Haddad PM. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. J Affect Disord 2005; 89:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bauer M, Pfennig A, Severus E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry 2013; 14:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Can J Psychiatry 2016; 61:540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baldessarini RJ, Tondo L, Ghiani C, Lepri B. Illness risk following rapid versus gradual discontinuation of antidepressants. Am J Psychiatry 2010; 167:934.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004; 50:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baldwin DS, Cooper JA, Huusom AK, Hindmarch I. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int Clin Psychopharmacol 2006; 21:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lejoyeux M, Adès J. Antidepressant discontinuation: a review of the literature. J Clin Psychiatry 1997; 58 Suppl 7:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Black DW, Wesner R, Gabel J. The abrupt discontinuation of fluvoxamine in patients with panic disorder. J Clin Psychiatry 1993; 54:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996; 16:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang LP, Plosker GL. Desvenlafaxine extended release. CNS Drugs 2008; 22:1061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montgomery SA, Fava M, Padmanabhan SK, et al. Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder. Int Clin Psychopharmacol 2009; 24:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hartford J, Kornstein S, Liebowitz M, et al. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 2007; 22:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palmer EC, Binns LN, Carey H. Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder. Ann Pharmacother 2014; 48:1030.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kyle JA, Dugan BD, Testerman KK. Milnacipran for treatment of fibromyalgia. Ann Pharmacother 2010; 44:1422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vandel P, Sechter D, Weiller E, et al. Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine. Hum Psychopharmacol 2004; 19:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fava M, Mulroy R, Alpert J, et al. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry 1997; 154:1760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parker G, Blennerhassett J. Withdrawal reactions associated with venlafaxine. Aust N Z J Psychiatry 1998; 32:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wellington K, Perry CM. Venlafaxine extended-release: a review of its use in the management of major depression. CNS Drugs 2001; 15:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montgomery SA, Kennedy SH, Burrows GD, et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004; 19:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berigan TR, Harazin JS. Bupropion-Associated Withdrawal Symptoms: A Case Report. Prim Care Companion J Clin Psychiatry 1999; 1:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benazzi F. Mirtazapine withdrawal symptoms. Can J Psychiatry 1998; 43:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klesmer J, Sarcevic A, Fomari V. Panic attacks during discontinuation of mirtazepine. Can J Psychiatry 2000; 45:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunner DL, Laird LK, Zajecka J, et al. Six-year perspectives on the safety and tolerability of nefazodone. J Clin Psychiatry 2002; 63 Suppl 1:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haria M, Fitton A, McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging 1994; 4:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Otani K, Tanaka O, Kaneko S, et al. Mechanisms of the development of trazodone withdrawal symptoms. Int Clin Psychopharmacol 1994; 9:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCormack PL. Vilazodone: a review in major depressive disorder in adults. Drugs 2015; 75:1915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang J, Mathis MV, Sellers JW, et al. The US Food and Drug Administration's perspective on the new antidepressant vortioxetine. J Clin Psychiatry 2015; 76:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baldwin DS, Chrones L, Florea I, et al. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol 2016; 30:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boulenger JP, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol 2012; 26:1408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garner EM, Kelly MW, Thompson DF. Tricyclic antidepressant withdrawal syndrome. Ann Pharmacother 1993; 27:1068.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dilsaver SC. Withdrawal phenomena associated with antidepressant and antipsychotic agents. Drug Saf 1994; 10:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ceccherini-Nelli A, Bardellini L, Cur A, et al. Antidepressant withdrawal: prospective findings. Am J Psychiatry 1993; 150:165.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 105323 Version 13.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Howlett JR, Stein MB, Nemeroff CB. Paroxetine. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.385.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Rosenbaum JF, Ionescu DF. Fluoxetine. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.335.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, 2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Recognising and managing antidepressant discontinuation symptoms
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Recognising and managing antidepressant discontinuation symptoms
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30292574" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13629473" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Clinical experience with imipramine (G22355) in the treatment of depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13793311" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Tofranil-treatment of endogenous depressions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30850328" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Tapering of SSRI treatment to mitigate withdrawal symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16683858" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Prospective studies of adverse events related to antidepressant discontinuation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25721705" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25721705" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31774947" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Understanding and Managing Withdrawal Syndromes After Discontinuation of Antidepressant Drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30501420" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : When Discontinuing SSRI Antidepressants Is a Challenge: Management Tips.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16913164" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Antidepressant discontinuation syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23359339" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Withdrawal and discontinuation phenomena associated with tranylcypromine: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30016772" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15906018" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16683857" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Physiologic mechanisms underlying the antidepressant discontinuation syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20075642" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31230675" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Tapering of SSRI treatment to mitigate withdrawal symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25003609" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Avoiding nocebo effects to optimize treatment outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9646889" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30732861" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The war on antidepressants: What we can, and can't conclude, from the systematic review of antidepressant withdrawal effects by Davies and Read.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31230676" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Tapering of SSRI treatment to mitigate withdrawal symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18515448" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9617977" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9219493" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Clinical management of antidepressant discontinuation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23459282" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Guidance for the discontinuation or switching of antidepressant therapies in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23459282" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Guidance for the discontinuation or switching of antidepressant therapies in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23320970" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : New onset hypertension following abrupt discontinuation of citalopram.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15291689" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Antidepressant-withdrawal mania:a critical review and synthesis of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20156925" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Antidepressant discontinuation manic states: a critical review of the literature and suggested diagnostic criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8971432" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21489048" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Hallucination induced by paroxetine discontinuation in patients with major depressive disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12211891" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Psychotic mania in bipolar II depression related to sertraline discontinuation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16636635" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Persistent sexual side effects after SSRI discontinuation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16636635" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Persistent sexual side effects after SSRI discontinuation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11448088" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Antidepressant discontinuation (withdrawal) symptoms presenting as 'stroke'.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7625480" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Fluoxetine withdrawal?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16683860" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9658279" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : SSRI discontinuation syndrome treated with fluoxetine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11347722" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Antidepressant discontinuation syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32699604" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : How user knowledge of psychotropic drug withdrawal resulted in the development of person-specific tapering medication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9549249" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : SSRI discontinuation syndrome related to fluvoxamine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12177584" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10827885" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11110006" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11110008" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16266753" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23879318" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27486148" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20478876" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Illness risk following rapid versus gradual discontinuation of antidepressants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15179022" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16528138" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9219488" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Antidepressant discontinuation: a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8486592" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : The abrupt discontinuation of fluvoxamine in patients with panic disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8889907" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Serotonin reuptake inhibitor withdrawal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18998743" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Desvenlafaxine extended release.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19779354" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17414743" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24811398" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20716692" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Milnacipran for treatment of fibromyalgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15570574" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9396960" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9588310" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Withdrawal reactions associated with venlafaxine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11524036" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Venlafaxine extended-release: a review of its use in the management of major depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15289700" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15014696" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Bupropion-Associated Withdrawal Symptoms: A Case Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9653542" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Mirtazapine withdrawal symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10986577" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Panic attacks during discontinuation of mirtazepine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11890563" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Six-year perspectives on the safety and tolerability of nefazodone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8019056" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8056996" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Mechanisms of the development of trazodone withdrawal symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26496736" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Vilazodone: a review in major depressive disorder in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25562777" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : The US Food and Drug Administration's perspective on the new antidepressant vortioxetine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26864543" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22495621" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8219442" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Tricyclic antidepressant withdrawal syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7912078" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Withdrawal phenomena associated with antidepressant and antipsychotic agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8417562" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Antidepressant withdrawal: prospective findings.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
